TY - JOUR
T1 - Staphylococcal phosphatidylglycerol antigens activate human T cells via CD1a
AU - Monnot, Gwennaëlle C.
AU - Wegrecki, Marcin
AU - Cheng, Tan-Yun
AU - Chen, Yi Ling
AU - Sallee, Brigitte N.
AU - Chakravarthy, Reka
AU - Karantza, Ioanna Maria
AU - Tin, Shin Yi
AU - Khaleel, Alexandra E.
AU - Monga, Isha
AU - Uwakwe, Laura N.
AU - Tillman, Alice
AU - Cheng, Bin
AU - Youssef, Soundos
AU - Ng, Soo Weei
AU - Shahine, Adam
AU - Garcia-Vilas, Javier A.
AU - Uhlemann, Anne Catrin
AU - Bordone, Lindsey A.
AU - Han, Arnold
AU - Rohde, Christine H.
AU - Ogg, Graham
AU - Moody, D. Branch
AU - Rossjohn, Jamie
AU - de Jong, Annemieke
N1 - Funding Information:
We thank the NIH Tetramer Core Facility for CD1 proteins, P. Sims and M. Finlayson for their advice regarding the analysis of single-cell RNA-seq data, A. Peschel for providing the S. aureus strain, Q. Cremers for assistance with ChemDraw and I. van Rhijn for critical reading of the manuscript. The work is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01 AR074037, K01 AR068475 and P30 AR069632 to A.d.J. and R01 AR048632 to D.B.M.) and the Wellcome Trust Collaborative Award (to D.B.M., G.O. and J.R.) as well as an Irving Scholarship (to A.d.J.). J.R. is supported by a National Health and Medical Research Council Investigator award. G.O. receives funding from the Medical Research Council UK and National Institute for Health and Care Research Oxford Biomedical Research Centre. This work was supported by the NCI Cancer Center Support Grant (P30 CA013696), used the Genomics and High Throughput Screening Shared Resource and was also supported by the National Center for Advancing Translational Sciences (UL1 TR001873), as well as funding to Columbia University Irving Medical Center flow core facilities through S10RR027050 and S10OD020056. We thank the staff of the MX1 beamline of the Australian Synchrotron, part of Australian Nuclear Science and Technology.
Funding Information:
We thank the NIH Tetramer Core Facility for CD1 proteins, P. Sims and M. Finlayson for their advice regarding the analysis of single-cell RNA-seq data, A. Peschel for providing the S. aureus strain, Q. Cremers for assistance with ChemDraw and I. van Rhijn for critical reading of the manuscript. The work is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01 AR074037, K01 AR068475 and P30 AR069632 to A.d.J. and R01 AR048632 to D.B.M.) and the Wellcome Trust Collaborative Award (to D.B.M., G.O. and J.R.) as well as an Irving Scholarship (to A.d.J.). J.R. is supported by a National Health and Medical Research Council Investigator award. G.O. receives funding from the Medical Research Council UK and National Institute for Health and Care Research Oxford Biomedical Research Centre. This work was supported by the NCI Cancer Center Support Grant (P30 CA013696), used the Genomics and High Throughput Screening Shared Resource and was also supported by the National Center for Advancing Translational Sciences (UL1 TR001873), as well as funding to Columbia University Irving Medical Center flow core facilities through S10RR027050 and S10OD020056. We thank the staff of the MX1 beamline of the Australian Synchrotron, part of Australian Nuclear Science and Technology.
Publisher Copyright:
© 2022, The Author(s), under exclusive licence to Springer Nature America, Inc.
PY - 2023/1
Y1 - 2023/1
N2 - Expressed on epidermal Langerhans cells, CD1a presents a range of self-lipid antigens found within the skin; however, the extent to which CD1a presents microbial ligands from bacteria colonizing the skin is unclear. Here we identified CD1a-dependent T cell responses to phosphatidylglycerol (PG), a ubiquitous bacterial membrane phospholipid, as well as to lysylPG, a modified PG, present in several Gram-positive bacteria and highly abundant in Staphylococcus aureus. The crystal structure of the CD1a–PG complex showed that the acyl chains were buried within the A′- and F′-pockets of CD1a, while the phosphoglycerol headgroup remained solvent exposed in the F′-portal and was available for T cell receptor contact. Using lysylPG and PG-loaded CD1a tetramers, we identified T cells in peripheral blood and in skin that respond to these lipids in a dose-dependent manner. Tetramer+CD4+ T cell lines secreted type 2 helper T cell cytokines in response to phosphatidylglycerols as well as to co-cultures of CD1a+ dendritic cells and Staphylococcus bacteria. The expansion in patients with atopic dermatitis of CD4+ CD1a–(lysyl)PG tetramer+ T cells suggests a response to lipids made by bacteria associated with atopic dermatitis and provides a link supporting involvement of PG-based lipid-activated T cells in atopic dermatitis pathogenesis.
AB - Expressed on epidermal Langerhans cells, CD1a presents a range of self-lipid antigens found within the skin; however, the extent to which CD1a presents microbial ligands from bacteria colonizing the skin is unclear. Here we identified CD1a-dependent T cell responses to phosphatidylglycerol (PG), a ubiquitous bacterial membrane phospholipid, as well as to lysylPG, a modified PG, present in several Gram-positive bacteria and highly abundant in Staphylococcus aureus. The crystal structure of the CD1a–PG complex showed that the acyl chains were buried within the A′- and F′-pockets of CD1a, while the phosphoglycerol headgroup remained solvent exposed in the F′-portal and was available for T cell receptor contact. Using lysylPG and PG-loaded CD1a tetramers, we identified T cells in peripheral blood and in skin that respond to these lipids in a dose-dependent manner. Tetramer+CD4+ T cell lines secreted type 2 helper T cell cytokines in response to phosphatidylglycerols as well as to co-cultures of CD1a+ dendritic cells and Staphylococcus bacteria. The expansion in patients with atopic dermatitis of CD4+ CD1a–(lysyl)PG tetramer+ T cells suggests a response to lipids made by bacteria associated with atopic dermatitis and provides a link supporting involvement of PG-based lipid-activated T cells in atopic dermatitis pathogenesis.
UR - http://www.scopus.com/inward/record.url?scp=85144670345&partnerID=8YFLogxK
U2 - 10.1038/s41590-022-01375-z
DO - 10.1038/s41590-022-01375-z
M3 - Article
C2 - 36550321
AN - SCOPUS:85144670345
SN - 1529-2908
VL - 24
SP - 110
EP - 122
JO - Nature Immunology
JF - Nature Immunology
IS - 1
ER -